X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/pharma/roche-offers-glimpse-columvi-polivy-combos-early-data-untreated-dlbcl-ph3-kicks
https://endpts.com/after-first-line-approval-in-dlbcl-debate-continues-around-benefit-from-roches-adc-polivy/
https://www.fiercepharma.com/marketing/roche-mirroring-novartis-guilty-most-serious-marketing-breach-polivy-website
https://www.fiercepharma.com/pharma/roche-wins-hard-fought-fda-approval-polivy-changing-20-years-lymphoma-practice
https://endpts.com/fda-adcomm-votes-11-2-to-expand-roches-polivy-label-in-dlbcl/
https://endpts.com/fda-raises-questions-in-adcomm-briefing-docs-for-roches-polivy-label-expansion/
https://www.thepharmaletter.com/article/fda-accepts-supplemental-biologics-license-application-for-roche-s-polivy-combination
https://www.labiotech.eu/trends-news/genentech-lymphoma-treatment/
https://www.expresspharma.in/european-commission-approves-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/
https://www.fiercepharma.com/pharma/roche-delays-polivys-blockbuster-lymphoma-filing-fda-asks-more-data
https://www.cancernetwork.com/view/progression-free-survival-boost-noted-with-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl
https://www.benzinga.com/general/biotech/21/12/24602009/roches-polivy-combo-boosts-survival-in-early-stage-lymphoma-patients
https://www.globenewswire.com/news-release/2021/12/14/2351759/0/en/Roche-s-Polivy-combination-reduced-the-risk-of-disease-worsening-or-death-by-27-in-people-with-previously-untreated-aggressive-form-of-lymphoma.html
https://www.fiercepharma.com/marketing/roche-s-polivy-to-hit-2-4b-as-doctors-highlight-significant-switching-to-newly-diagnosed
https://www.fiercepharma.com/pharma/roche-snags-coveted-polivy-win-newly-diagnosed-lymphoma-but-it-enough-to-shift-2-decades
https://www.bloomberg.com/press-releases/2020-09-24/health-canada-grants-market-authorization-to-polivy-polatuzumab-vedotin-for-the-treatment-of-adult-patients-with-relapsed
https://www.chugai-pharm.co.jp/english/news/detail/20200630113000_737.html
https://www.fiercepharma.com/pharma/roche-s-new-cancer-med-polivy-lacks-long-term-evidence-nice-says-rejection
http://www.pharmatimes.com/news/polivy_struck_by_nice_no_1327011
https://www.chugai-pharm.co.jp/news/cont_file_dl.php?f=200213ePolatuzumab+vedotin_JO40762_topline.pdf&src=[%0],[%1]&rep=130,697
http://www.pharmatimes.com/news/eu_clears_roches_polivy_for_certain_lymphomas_1322933
https://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-issues-updated-list-of-new-specialty-drugs-300903210.html
https://www.fiercepharma.com/pharma/roche-touts-phase-2-gazyva-data-lupus-nephritis-same-day-as-new-approval
https://www.fiercepharma.com/pharma/roche-snags-fda-approval-for-polivy-combo-certain-dlbcl-patients
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761121
https://endpts.com/a-top-roche-experimental-hematology-drug-polatuzumab-vedotin-wins-speedy-fda-review/
https://endpts.com/gilead-locks-in-daniel-oday-as-ceo-tapping-the-roche-vet-to-rejuvenate-growth/
Market Place
Share 
